Unknown

Dataset Information

0

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus.

ABSTRACT: Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.

SUBMITTER: Dong F 

PROVIDER: S-EPMC6347601 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus.

Dong Fangfang F   Li Dandan D   Wen Dan D   Li Suhua S   Zhao Chaoyue C   Qi Yue Y   Jangra Rohit K RK   Wu Cuiping C   Xia Dequan D   Zhang Xing X   Deng Fei F   Chandran Kartik K   Zou Zhen Z   Yuan Fei F   Zheng Aihua A  

NPJ vaccines 20190125

Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent  ...[more]

Similar Datasets

Unknown Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice.
| S-EPMC7112229 | biostudies-literature
Transcriptomics Molecular correlates of vaccine-induced protection against typhoid fever
2023-07-19 | GSE217667 | GEO
Unknown Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model.
| S-EPMC6936527 | biostudies-literature
Unknown Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease.
| S-EPMC6816409 | biostudies-other
Unknown Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.
| S-EPMC6773275 | biostudies-literature
Unknown Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.
| S-EPMC4742904 | biostudies-literature
Proteomics Serum Proteomics of Severe Fever with Thrombocytopenia Syndrome Patients
2022-10-13 | PXD033989 | Pride
Unknown Endemic Severe Fever with Thrombocytopenia Syndrome, Vietnam.
| S-EPMC6478219 | biostudies-literature
Unknown A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome.
| S-EPMC7886154 | biostudies-literature
Unknown Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration.
| S-EPMC6203377 | biostudies-literature